This report provides projections of the incidence of Alzheimer disease (AD) that will occur among older Americans in the future. Education adjusted age-specific incidence rates of clinically diagnosed probable AD were obtained from stratified random samples of residents 65 years of age and older in a geographically defined community. These rates were applied to U.S. Census Bureau projections of the total U.S. population by age and sex to estimate the number of people newly affected each year.
The study estimated that “in 2010, there were 4.7 million individuals aged 65 years or older with AD dementia (95% confidence interval [CI] = 4.0-5.5). Of these, 0.7 million (95% CI = 0.4-0.9) were between 65 and 74 years, 2.3 million were between 75 and 84 years (95% CI = 1.7-2.9), and 1.8 million were 85 years or older (95% CI = 1.4-2.2). The total number of people with AD dementia in 2050 is projected to be 13.8 million, with 7.0 million aged 85 years or older.
It is anticipated that the proportion of new onset cases who are age 85 or older will increase from 40% in 1995 to 62% in 2050 when the youngest of the baby boomers will attain that age. Without progress in preventing or delaying onset of Alzheimer disease, both the number of people with Alzheimer disease and the proportion of the total population affected will increase substantially.”
Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050 Hebert, Liesi E.; Beckett, Laurel A.; Scherr, Paul A.; Evans, Denis A. Neurology. 2013 May 7;80(19):1778-83.
The need for treatment interventions if not to cure, to at least stabilize or slow progression of Alzheimer’s disease (which accounts for 80% cases of dementia) is one of the greatest healthcare challenges of our time. The cognitive rehabilitative, professional memory training interventions offered by MTCA have been shown to achieve these goals. MTCA is always working to develop new techniques and conducting research to strengthen our ability to help patients and families, providers and healthcare organizations, to meet the goals of delaying onset and stabilizing progression of the neurodegenerative process of Alzheimer’s disease.